In our cohort of SPNs, we found that a lack of or reduced expression of both KDM6A and BAP1 is enriched in metastatic cases, suggesting that their function is a barrier to the development of metastatic disease at least in a subset of SPNs. Here, BAP1 is linked to metastatic neoplasm.